{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T01:39:44Z","timestamp":1776908384108,"version":"3.51.2"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important treatment option for hematologic diseases. However, limited studies have evaluated the prognosis of patients receiving single human leukocyte antigen (HLA) mismatched unrelated donor allo-HSCT (HLA 9\/10 MMUD-HSCT) compared to those receiving fully matched unrelated donor allo-HSCT (10\/10 MUD-HSCT). This study retrospectively analyzed 126 cases of unrelated donor allo-HSCT (URD-HSCT) at our center, in which anti-human thymocyte globulin (ATG, 7.5\u00a0mg\/kg) was used as a graft-versus-host disease (GVHD) prophylaxis strategy. The MUD-HSCT group had a significantly lower incidence of grade II\u2013IV acute GVHD (13.89% vs. 35.19% in the MMUD-HSCT group, <jats:italic>p<\/jats:italic>\u2009=\u20090.005). In contrast, the incidence of moderate-to-severe chronic GVHD (cGVHD) did not differ significantly between the two groups (16.67% vs. 29.63%, <jats:italic>p<\/jats:italic>\u2009=\u20090.083). The median follow-up time was 16.98\u00a0months (range: 7.88\u201338.55). There were no significant differences between the two groups in the 1-year cumulative incidence of relapse (CIR) (<jats:italic>p<\/jats:italic>\u2009=\u20090.707), 3-year CIR (<jats:italic>p<\/jats:italic>\u2009=\u20090.764), 1-year disease-free survival (DFS) (<jats:italic>p<\/jats:italic>\u2009=\u20090.954), 3-year DFS (<jats:italic>p<\/jats:italic>\u2009=\u20090.888), 1-year overall survival (OS) (<jats:italic>p<\/jats:italic>\u2009=\u20090.611), 3-year OS (<jats:italic>p<\/jats:italic>\u2009=\u20090.796), 3-year non-relapse mortality (NRM) (<jats:italic>p<\/jats:italic>\u2009=\u20090.711), or GVHD-free relapse-free survival (GRFS) (<jats:italic>p<\/jats:italic>\u2009=\u20090.546). The estimated median OS and DFS times were not reached in either group. In conclusion, under an ATG-based GVHD prophylaxis regimen, HLA 9\/10 MMUD-HSCT is a viable alternative donor option, offering comparable clinical outcomes to those of fully matched unrelated donor HSCT.<\/jats:p>","DOI":"10.1007\/s44313-025-00082-6","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T13:43:49Z","timestamp":1748958229000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of HLA locus mismatch on peripheral blood allogeneic hematopoietic stem cell transplantation from unrelated donors using an ATG-based GVHD prophylaxis strategy"],"prefix":"10.1007","volume":"60","author":[{"given":"Jiawen","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kourong","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"issue":"3","key":"82_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.bbmt.2015.09.012","volume":"22","author":"K Besse","year":"2016","unstructured":"Besse K, Maiers M, Confer D, et al. On Modeling Human Leukocyte Antigen-Identical Sibling Match Probability for Allogeneic Hematopoietic Cell Transplantation: Estimating the Need for an Unrelated Donor Source. Biol Blood Marrow Transplant. 2016;22(3):410\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"82_CR2","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.bbmt.2015.12.012","volume":"22","author":"K Buck","year":"2016","unstructured":"Buck K, Wadsworth K, Setterholm M, et al. High-Resolution Match Rate of 7\/8 and 9\/10 or Better for the Be The Match Unrelated Donor Registry. Biol Blood Marrow Transplant. 2016;22(4):759\u201363.","journal-title":"Biol Blood Marrow Transplant"},{"key":"82_CR3","doi-asserted-by":"crossref","unstructured":"Xu L P, Lu P H, Wu D P, et al. Hematopoietic stem cell transplantation activity in China 2022\u20132023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group. Bone Marrow Transplant.\u00a02024;59(12):1726\u201334.","DOI":"10.1038\/s41409-024-02419-8"},{"issue":"1","key":"82_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, et al. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22(1):4\u201310.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"82_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2016-07-686642","volume":"129","author":"SJ Lee","year":"2017","unstructured":"Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017;129(1):30\u20137.","journal-title":"Blood"},{"key":"82_CR6","doi-asserted-by":"publisher","first-page":"1005042","DOI":"10.3389\/fonc.2022.1005042","volume":"12","author":"MU Mushtaq","year":"2022","unstructured":"Mushtaq MU, Shahzad M, Tariq E, et al. Outcomes with mismatched unrelated donor allogeneic hematopoietic stem cell transplantation in adults: A systematic review and meta-analysis. Front Oncol. 2022;12:1005042.","journal-title":"Front Oncol"},{"issue":"11","key":"82_CR7","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.2014.58.9747","volume":"33","author":"C Peters","year":"2015","unstructured":"Peters C, Schrappe M, von Stackelberg A, et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. J Clin Oncol. 2015;33(11):1265\u201374.","journal-title":"J Clin Oncol"},{"issue":"1","key":"82_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1182\/hematology.2022000326","volume":"2022","author":"SR Spellman","year":"2022","unstructured":"Spellman SR. Hematology 2022-what is complete HLA match in 2022? Hematology Am Soc Hematol Educ Program. 2022;2022(1):83\u20139.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"82_CR9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1182\/blood-2015-08-663823","volume":"127","author":"C Kollman","year":"2016","unstructured":"Kollman C, Spellman SR, Zhang MJ, et al. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2016;127(2):260\u20137.","journal-title":"Blood"},{"issue":"5","key":"82_CR10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41409-017-0084-2","volume":"53","author":"H Saito","year":"2018","unstructured":"Saito H, Ito M, Kato S, et al. The Japan Marrow Donor Program, 25 years of experience in achieving 20,000 bone marrow transplantations: organization structure, activity, and financial basis. Bone Marrow Transplant. 2018;53(5):609\u201316.","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"82_CR11","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1634\/theoncologist.2017-0009","volume":"22","author":"TL Kindwall-Keller","year":"2017","unstructured":"Kindwall-Keller TL, Ballen KK. Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017! Oncologist. 2017;22(9):1125\u201334.","journal-title":"Oncologist"},{"issue":"6","key":"82_CR12","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/CCO.0000000000000485","volume":"30","author":"CS Lozano","year":"2018","unstructured":"Lozano CS, Altaf SY, Olavarria E. Allogeneic stem cell transplantation from unrelated donors in acute leukaemia. Curr Opin Oncol. 2018;30(6):418\u201324.","journal-title":"Curr Opin Oncol"},{"issue":"13","key":"82_CR13","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","volume":"110","author":"SJ Lee","year":"2007","unstructured":"Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13):4576\u201383.","journal-title":"Blood"},{"key":"82_CR14","doi-asserted-by":"crossref","unstructured":"Li L, Chen Y, Chen T, et al. Mismatched unrelated donors allogeneic hematopoietic stem cell transplantation with antithymocyte globulin for hematological malignancies: a multicenter retrospective study in China. Bone Marrow Transplantation.\u00a02025;60(2):201\u201310.","DOI":"10.1038\/s41409-024-02454-5"},{"issue":"2","key":"82_CR15","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00277-020-04317-7","volume":"100","author":"R Bailen","year":"2021","unstructured":"Bailen R, Kwon M, Pascual-Cascon MJ, et al. Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation. Ann Hematol. 2021;100(2):541\u201353.","journal-title":"Ann Hematol"},{"issue":"10","key":"82_CR16","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jtct.2022.07.021","volume":"28","author":"RS Mehta","year":"2022","unstructured":"Mehta RS, Saliba RM, Rondon G, et al. Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation. Transplant Cell Ther. 2022;28(10):691\u20135.","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"82_CR17","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/s41375-024-02225-7","volume":"38","author":"O Penack","year":"2024","unstructured":"Penack O, Abouqateb M, Peczynski C, et al. ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation? Leukemia. 2024;38(5):1156\u201363.","journal-title":"Leukemia"},{"issue":"25","key":"82_CR18","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bolanos-Meade","year":"2023","unstructured":"Bolanos-Meade J, Hamadani M, Wu J, et al. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. N Engl J Med. 2023;388(25):2338\u201348.","journal-title":"N Engl J Med"},{"issue":"3","key":"82_CR19","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/bjh.19031","volume":"203","author":"M Aydin","year":"2023","unstructured":"Aydin M, de Leeuw DC, Rutten CE, et al. ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non-myeloablative conditioning. Br J Haematol. 2023;203(3):439\u201345.","journal-title":"Br J Haematol"},{"issue":"1","key":"82_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41408-024-00990-3","volume":"14","author":"E Brissot","year":"2024","unstructured":"Brissot E, Labopin M, Labussiere H, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10\/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial. Blood Cancer J. 2024;14(1):31.","journal-title":"Blood Cancer J"},{"issue":"6","key":"82_CR21","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/ejh.13230","volume":"102","author":"S Prem","year":"2019","unstructured":"Prem S, Atenafu EG, Al-Shaibani Z, et al. Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants. Eur J Haematol. 2019;102(6):486\u201393.","journal-title":"Eur J Haematol"},{"key":"82_CR22","doi-asserted-by":"publisher","first-page":"101080","DOI":"10.1016\/j.blre.2023.101080","volume":"62","author":"R Dulery","year":"2023","unstructured":"Dulery R, Brissot E, Mohty M. Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies. Blood Rev. 2023;62.","journal-title":"Blood Rev"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00082-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-025-00082-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00082-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T13:43:52Z","timestamp":1748958232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-025-00082-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["82"],"URL":"https:\/\/doi.org\/10.1007\/s44313-025-00082-6","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all patients for the publication of any potentially identifiable data included in this article. The study design was approved by the ethics committee of The First Affiliated Hospital of Nanjing Medical University (Approval No. 2023-SR-413).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}